TABLE 4

Prognostic Factors on Tumor Control After SABR by Cox Proportional Hazards Model

VariableCrude hazard ratioPAdjusted hazard ratio*P
Age, ≥60 vs. <60 y1.23 (0.38–3.95)0.729
Sex, female vs. male0.38 (0.05–2.93)0.354
ECOG, 1/2 vs. 00.99 (0.33–2.98)0.985
AJCC stage, III/IV vs. I/II2.09 (0.72–6.05)0.176
CLIP score, >1 vs. ≤11.87 (0.62–5.65)0.266
Child–Pugh B vs. A0.04 (0.01–471.94)0.509
AFP, >100 vs. ≤100 ng/mL1.05 (0.33–3.34)0.941
SABR dose, >40 vs. ≤40 Gy0.96 (0.33–2.78)0.942
Tumor volume, >40 vs. ≤40 cm32.65 (0.83–8.47)0.1001.79 (0.44–7.39)0.419
Visual 18F-FDG uptake, + vs. −2.24 (0.77–6.47)0.1381.95 (0.50–7.52)0.334
TSUVmax, >3.2 vs. ≤3.24.99 (1.10–22.51)0.0379.40 (1.18–74.76)0.034
TSUVmean, >2.9 vs. ≤2.91.38 (0.48–3.98)0.5521.31 (0.42–4.06)0.644
TSUVmax/LSUVmax, >1.15 vs. ≤1.152.23 (0.74–6.71)0.1521.61 (0.45–5.71)0.461
TSUVmax/LSUVmean, >1.25 vs. ≤1.252.43 (0.68–8.75)0.1731.31 (0.28–6.07)0.734
CT/18F-FDG PET score, >4 vs. ≤45.23 (1.17–23.47)0.0314.96 (1.05–23.40)0.043
  • * Adjusted for sex, AJCC stage, CLIP score, Child–Pugh classification, and tumor volume.

  • Adjusted for sex, AJCC stage, CLIP score, and Child–Pugh classification.

  • ECOG = Eastern Cooperative Oncology Group.

  • Data in parentheses are 95% confidence intervals.